Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

R. Bissonnette*, T. Luger, D. Thaçi, D. Toth, A. Lacombe, S. Xia, R. Mazur, M. Patekar, P. Charef, M. Milutinovic, C. Leonardi, U. Mrowietz

*Corresponding author for this work
64 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science